Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Tumour Necrosis Factor Inhibitor Drugs Market Outlook

The global tumour necrosis factor inhibitor drugs market attained a value of around USD 41.16 billion in 2023. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of around 0.7% to reach USD 43.80 billion by 2032.

Global Tumour Necrosis Factor Inhibitor Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The market is significantly being aided by the growing awareness among consumers about Tumour Necrosis Factor (TNF). North America is the leading region, whereas the Asia Pacific is expected to witness the fastest growth in the forecast period.

Market Segmentation

Tumour necrosis factor inhibitor are organic medicines derived from humans or animals’ tissues and most widely used by blocking the inflammatory substance, that is, the tumour necrosis factor in the body to stop inflammation and progression of the disease. It is recommended mainly for treating multiple inflammatory disorders, including rheumatoid arthritis and psoriasis.

Global Tumour Necrosis Factor Inhibitor Drugs Market By Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on type, the market can be divided into:

  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • Biosimilars

The market can be broadly categorised based on its end-uses into:

  • Rheumatoid arthritis
  • Psoriasis
  • Psoriatic Arthritis
  • Crohn's Disease
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Hidradenitis Suppurativa
  • Others

The EMR report looks into the regional markets of tumour necrosis factor inhibitor drugs like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Global Tumour Necrosis Factor Inhibitor Drugs Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

The market for tumour necrosis factor inhibitor drugs is driven by the increased prevalence of several inflammatory disorders, like rheumatoid arthritis and inflammatory bowel disease in North America. Europe has also been a significant part of the global market due to a robust geriatric population, which is more vulnerable to inflammatory conditions. The increased incidences of different inflammatory diseases and the entrance in the market of the biosimilar are likely to increase both the availability and the usage of the tumour necrosis factor inhibitor drugs, which, in effect, will boost the market during the forecast period. In addition, low manufacturing costs in China and India have led to an increase in the number of plants attracting pharmaceutical and biotechnological giants from all over the world.

Competitive Landscape

The report presents a detailed analysis of the following key players in the global tumour necrosis factor inhibitor drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • AbbVie, Inc. (NYSE: ABBV)
  • Amgen, Inc. 
  • Johnson & Johnson Services, Inc.
  • UCB S.A. (EBR: UCB)
  • Pfizer, Inc.  (NYSE: PFE)
  • Novartis International AG (SWX: NOVN) 
  • Merck & Co., Inc. (NYSE: MRK)
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • End Use
  • Region
Breakup by Type
  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • Biosimilars
Breakup by End Use
  • Rheumatoid arthritis
  • Psoriasis
  • Psoriatic arthritis
  • Crohn's Disease
  • Ulcerative colitis
  • Ankylosing Spondylitis
  • Juvenile idiopathic arthritis
  • Hidradenitis suppurativa
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • AbbVie, Inc. (NYSE: ABBV)
  • Amgen, Inc. (NASDAQ: AMGN)
  • Johnson & Johnson Services, Inc.
  • UCB S.A. (EBR: UCB)
  • Pfizer, Inc.  (NYSE: PFE)
  • Novartis International AG (SWX: NOVN) 
  • Merck & Co., Inc. (NYSE: MRK)
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

In 2023, the global tumour necrosis factor inhibitor drugs market attained a value of nearly USD 41.16 billion.

The market is projected to grow at a CAGR of 0.7% between 2024 and 2032.

The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach about USD 43.80 billion by 2032.

The major drivers of the industry, such as the growing awareness among consumers about TNF, increased prevalence of several inflammatory disorders, and low manufacturing costs, are expected to aid the market growth.

The key market trend guiding the industry growth includes the growing development and manufacture of new products.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.

The leading types of tumour necrosis factor inhibitor drugs in the industry are Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and biosimilars.

The major end uses of these drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, and hidradenitis suppurativa, among others.

The major players in the industry are AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., UCB S.A., Pfizer, Inc., Novartis International AG, and Merck & Co., Inc., among others.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124